Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759589 | 0.84 | DDB1 (0.41) | GPR3KDM4ELMNAALDH1A1POLB | |
| SCHEMBL861330 | 0.75 | HSD17B10 (0.47) | GPR3KDM4ELMNAALDH1A1POLB | |
| SCHEMBL16328883 | 0.71 | KDM4E (0.35) | GPR3KDM4ELMNAALDH1A1POLB | |
| SCHEMBL12759587 | 0.71 | MAPT (0.37) | GPR3KDM4ELMNAALDH1A1POLB | |
| SCHEMBL12759590 | 0.71 | MAPT (0.39) | GPR3KDM4ELMNAALDH1A1POLB | |
| SCHEMBL13325840 | 0.69 | ADORA2A (0.53) | KDM4ELMNAALDH1A1HSD17B10TSHR | |
| SCHEMBL12759626 | 0.67 | L3MBTL1 (0.37) | KDM4ELMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL3356083 | 0.67 | ADORA2A (0.46) | KDM4ELMNAALDH1A1POLBGLA | |
| SCHEMBL13309569 | 0.66 | CYP1A2 (0.38) | KDM4ELMNAALDH1A1POLBMAPT | |
| SCHEMBL29929754 | 0.66 | ADORA2A (0.35) | KDM4ELMNAALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062084-B2 | Method of forming metal complex compound, and organic electroluminescence device | UDC Ireland (IE) | 2015-06-23 | — | — | US | disclosed |
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110050093-A1 | METHOD OF FORMING METAL COMPLEX COMPOUND, AND ORGANIC ELECTROLUMINESCENCE DEVICE | ZFR, PORCN, OR10J3 | GPR3 4569/4885KDM4E 2514/4885LMNA 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.